Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 205-215

  Tan, Qiang ^a,b   Li, Jing ^a   Yin, Han Wei ^b   Wang, Li Hui ^a   Tang, Wan Chen ^a   Zhao, Fang ^a   Liu, Xin Min ^b   Zeng, Hui Hui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Cisplatin; Combination chemotherapy; Ethaselen; Non small cell lung cancer; Synergistic effect; Thioredoxin reductase inhibitor

Indexed keywords

CISPLATIN; ETHASELEN; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; ORGANOSELENIUM DERIVATIVE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY INJURY; LIPID PEROXIDATION; LIVER INJURY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIPID PEROXIDATION; LIVER; LIVER FUNCTION TESTS; MICE; MICE, NUDE; ORGANOSELENIUM COMPOUNDS; THIOREDOXIN-DISULFIDE REDUCTASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952238029     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9235-7     Document Type: Article

References (48)

1. Karin A (2006) Mammalian thioredoxin reductase as a drug target in anticancer therapy through direct apoptosis induction by selenium compromised forms of the protein. Karolinska University Press, Sweden
2. G Powis D Mustacich A Coon 2000 The role of the redox protein thioredoxin in cell growth and cancer Free Radic Biol Med 29 3-4 312 322 10.1016/S0891-5849(00)00313-0 1:CAS:528:DC%2BD3cXnslWmt7o%3D 11035260 doi:10.1016/S0891-5849(00)00313-0
3. G Powis DL Kirkpatrick 2007 Thioredoxin signaling as a target for cancer therapy Curr Opin Pharmacol 7 4 392 397 10.1016/j.coph.2007.04.003 1:CAS:528:DC%2BD2sXpsFKqs74%3D 17611157 doi:10.1016/j.coph.2007.04.003 (Pubitemid 47289261)
4. M Selenius AP Fernandes O Brodin M Björnstedt AK Rundlöf 2008 Treatment of lung cancer cells with cytotoxic levels of sodium selenite: Effects on the thioredoxin system Biochem Pharmacol 75 11 2092 2099 10.1016/j.bcp.2008.02.028 1:CAS:528:DC%2BD1cXlvVWhs78%3D 18405881 doi:10.1016/j.bcp.2008.02.028
5. S Urig K Becker 2006 On the potential of thioredoxin reductase inhibitors for cancer therapy Semin Cancer Biol 16 6 452 465 10.1016/j.semcancer.2006.09. 004 1:CAS:528:DC%2BD28Xht1eqt7%2FL 17056271 doi:10.1016/j.semcancer.2006.09.004 (Pubitemid 44780136)
6. D Magda RA Miller 2006 Motexafin gadolinium: A novel redox active drug for cancer therapy Semin Cancer Biol 16 6 466 476 10.1016/j.semcancer.2006.09. 002 1:CAS:528:DC%2BD28Xht1eqt7%2FE 17112739 doi:10.1016/j.semcancer.2006.09.002 (Pubitemid 44780135)
7. J Lu LV Papp J Fang S Rodriguez-Nieto B Zhivotovsky A Holmgren 2006 Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity Cancer Res 66 8 4410 4418 10.1158/0008-5472.CAN-05-3310 1:CAS:528:DC%2BD28XjsFSlur0%3D 16618767 doi:10.1158/0008-5472.CAN-05-3310
8. F Zhao J Yan SJ Deng LX Lan F He B Kuang HH Zeng 2006 A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines Cancer Lett 236 1 46 53 10.1016/j.canlet.2005.05.010 1:CAS:528:DC%2BD28XjvVGgs7w%3D 15982805 doi:10.1016/j.canlet.2005.05.010
9. CJ Shi LZ Yu FG Yang J Yan HH Zeng 2003 A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines Biochem Biophys Res Commun 309 3 578 583 10.1016/j.bbrc.2003.08.032 1:CAS:528: DC%2BD3sXntVGmtrw%3D 12963029 doi:10.1016/j.bbrc.2003.08.032 (Pubitemid 37083290)
10. ZF Peng LX Lan F Zhao J Li Q Tan HW Yin HH Zeng 2008 A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells J Zhejiang Univ Sci B 9 1 16 21 10.1631/jzus.B071605 1:CAS:528: DC%2BD1cXkt1Sqsro%3D 18196608 doi:10.1631/jzus.B071605 (Pubitemid 351436993)
11. SJ Deng B Kuang X Zhou J Yan F Zhao XY Jia HH Zeng 2003 BBSKE, 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane, induced cell death in tumor cells Beijing Da Xue Xue Bao 35 1 108 109 1:CAS:528:DC%2BD3sXptlejs74%3D
12. YR Wang JJ Xiao XM Dong SC Meng SJ Deng B Kuang J Yan F Zhao HH Zeng 2005 The antitumor activity of Shuang-Xi-Zuo-Wan-1 in C57/BL mice Beijing Da Xue Xue Bao 37 4 421 424 1:CAS:528:DC%2BD28XlvVGhsL0%3D 16086067
13. FX Xing S Li X Ge C Wang HH Zeng D Li L Dong 2008 The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo Oral Oncol 44 10 963 969 10.1016/j.oraloncology.2007.12.001 1:CAS:528:DC%2BD1cXhtFekurvJ 18282784 doi:10.1016/j.oraloncology.2007.12.001
14. YR Wang JJ Xiao XM Dong SC Meng SJ Deng B Kuang J Yan F Zhao HH Zeng 2006 Immune regulating activity of a novel organoselenium compound ethaselen-1 in C57 /BL mice Beijing Da Xue Xue Bao 38 6 634 639 1:CAS:528:DC%2BD1cXhvFOitb8%3D 17173086
15. LX Lan F Zhao Y Wang HH Zeng 2007 The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-κB- dependent pathway Eur J Pharmacol 555 2-3 83 92 10.1016/j.ejphar.2006.10.037 1:CAS:528:DC%2BD2sXls1Cltw%3D%3D 17116300 doi:10.1016/j.ejphar.2006.10.037 (Pubitemid 46048803)
16. YP Ho SC Au-Yeung KK To 2003 Platinum-based anticancer agents: innovative design strategies and biological perspectives Med Res Rev 23 5 633 655 10.1002/med.10038 1:CAS:528:DC%2BD3sXnsFCgsb0%3D 12789689 doi:10.1002/med.10038 (Pubitemid 37038095)
17. G Momekov A Bakalova M Karaivanova 2005 Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity Curr Med Chem 12 19 2177 2191 10.2174/ 0929867054864877 1:CAS:528:DC%2BD2MXpsVegurk%3D 16178779 doi:10.2174/ 0929867054864877 (Pubitemid 41179706)
18. PJ Loehrer LH Einhorn 1984 Drugs five years later Cisplatin. Ann Intern Med 100 5 704 713 1:CAS:528:DyaL2cXktlalt78%3D
19. T Sasada H Nakamura S Ueda N Sato Y Kitaoka Y Gon A Takabayashi G Spyrou A Holmgren J Yodoi 1999 Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum(II) Free Radic Biol Med 27 5-6 504 514 10.1016/S0891-5849(99)00101-X 1:CAS:528: DyaK1MXls12ntrc%3D 10490269 doi:10.1016/S0891-5849(99)00101-X (Pubitemid 29408635)
20. SI Lee MK Brown A Eastman 1999 Comparison of the efficacy of 7-Hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines Biochem Pharmacol 58 11 1713 1721 10.1016/S0006-2952(99)00258-0 1:CAS:528: DyaK1MXntVCgtbs%3D 10571245 doi:10.1016/S0006-2952(99)00258-0 (Pubitemid 29505411)
21. MJ Egorin RC Moschel ME Dolan 2005 Effect of cell cycle inhibition on cisplatin-induced cytotoxicity J Pharmacol Exp Ther 312 1 206 213 15304523
22. E Crescenzi A Chiaviello G Canti E Reddi BM Veneziani G Palumbo 2006 Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299) Mol Cancer Ther 5 3 776 785 10.1158/1535-7163.MCT-05-0425 1:CAS:528:DC%2BD28Xitl2ksrk%3D 16546993 doi:10.1158/1535-7163.MCT-05-0425
23. GS Baldew JG McVie MA van der Valk G Los JJ de Goeij NP Vermeulen 1990 Selective reduction of cis-Diamminedichloroplatinum (II) nephrotoxicity by Ebselen Cancer Res 50 21 7031 7036 1:CAS:528:DyaK3MXivFc%3D 2208170
24. HH Aung SR Mehendale CZ Wang JT Xie E McEntee CS Yuan 2007 Cisplatin's tumoricidal effect on human breast carcinoma MCF-7 cells was not attenuated by American ginseng Cancer Chemother Pharmacol 59 3 369 374 10.1007/s00280-006- 0278-6 1:CAS:528:DC%2BD28XhtlCksb%2FI 16799811 doi:10.1007/s00280-006-0278-6 (Pubitemid 46025524)
25. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 3 621 681 10.1124/pr.58.3.10 1:CAS:528:DC%2BD28XhtVOhtLfL 16968952 doi:10.1124/pr.58.3.10 (Pubitemid 44403686)
26. H Miyake A Tolcher ME Gleave 1999 Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model Cancer Res 59 16 4030 4034 1:CAS:528:DyaK1MXlsVOltbo%3D 10463603
27. A Holmgren M Bjornstedt 1995 Thioredoxin and thioredoxin reductase Methods Enzymol 252 1 199 208 10.1016/0076-6879(95)52023-6 1:CAS:528: DyaK2MXptFOrtL4%3D 7476354 doi:10.1016/0076-6879(95)52023-6
28. AD Smith CA Guidry VC Morris OA Levander 1999 Aurothioglucose inhibits murine thioredoxin reductase activity in vivo J Nutr 129 1 194 198 1:CAS:528:DyaK1MXlslKqtg%3D%3D 9915899
29. ZA Placer LL Cushman BC Johnson 1966 Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems Anal Biochem 16 2 359 364 10.1016/0003-2697(66)90167-9 1:CAS:528:DyaF28XksFymsLs%3D 6007581 doi:10.1016/0003-2697(66)90167-9
30. RA Lawrence RF Burk 1976 Glutathione peroxidase activity in selenium-deficient rat liver Biochem Biophys Res Commun 71 4 952 958 10.1016/0006-291X(76)90747-6 1:CAS:528:DyaE28XlsVWls7s%3D 971321 doi:10.1016/0006-291X(76)90747-6
31. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 10.3322/canjclin.55.2.74 15761078 doi:10.3322/canjclin.55.2.74
32. PD Kiernan PR Graling VL Hetrick BE Vaughan MJ Sheridan JK Lee 2004 A pragmatic and successful approach to treating non small-cell lung carcinoma AORN J 80 5 840 857 10.1016/S0001-2092(06)60507-3 15566211 doi:10.1016/S0001- 2092(06)60507-3
33. A Gajra N Newman GP Gamble NZ Abraham LJ Kohman SL Graziano 2003 Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease Lung Cancer 42 1 51 57 10.1016/S0169-5002(03)00285- X 14512187 doi:10.1016/S0169-5002(03)00285-X (Pubitemid 37153135)
34. DM Parkin FI Bray SS Devessa 2001 Cancer burden for the year 2000: the global picture Eur J Cancer 37 suppl 8 64 66 doi:10.1016/S0959-8049(01)00267-2
35. ZF Sun P Yang T Singh J Dhindsa JE Larsen KM Fong NK Hayward A Potti DH Harpole Jr JR Nevins 2007 Refining prognosis in non-small-cell lung cancer N Engl J Med 356 2 189 191 10.1056/NEJMc062409 1:CAS:528:DC%2BD2sXksVOmsA%3D%3D 17215540 doi:10.1056/NEJMc062409
36. Non-small Cell Lung Cancer Collaborative Group 1995 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 7010 899 908
37. A Bearz I Garassino R Cavina A Favaretto M Boccalon R Talamini M Berretta S Spazzapan C Simonelli A Santoro U Tirelli 2008 Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study Lung Cancer 60 2 240 245 10.1016/j.lungcan.2007.10.008 18022729 doi:10.1016/j.lungcan.2007.10.008 (Pubitemid 351609151)
38. NI Weijl FJ Cleton S Osanto 1997 Free radicals and antioxidants in chemotherapy-induced toxicity Cancer Treat Rev 23 4 209 240 10.1016/S0305- 7372(97)90012-8 1:CAS:528:DyaK2sXntVGmt7g%3D 9377594 doi:10.1016/S0305-7372(97) 90012-8 (Pubitemid 27464149)
39. G Chu 1994 Cellular responses to cisplatin: The roles of DNA binding proteins and DNA repair J Biol Chem 269 2 787 790 1:CAS:528:DyaK2cXht1eqtrs%3D 8288625
40. TC Chou P Talalay 1984 Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 10.1016/0065-2571(84)90007-4 1:CAS:528:DyaL2cXktlaksLk%3D 6382953 doi:10.1016/0065-2571(84)90007-4
41. M Naziroglu A Karaoǧlu AO Aksoy 2004 Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats Toxicology 195 2-3 221 230 10.1016/j.tox.2003.10. 012 1:CAS:528:DC%2BD2cXmvF2itg%3D%3D 14751677 doi:10.1016/j.tox.2003.10.012 (Pubitemid 38125121)
42. Y Soini K Kahlos U Näpänkangas R Kaarteenaho-Wiik M Säily P Koistinen P Pääakkö A Holmgren VL Kinnula 2001 Widespread Expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma Clin Cancer Res 7 6 1750 1757 1:CAS:528:DC%2BD3MXltV2hs7c%3D 11410516 (Pubitemid 32708645)
43. ES Arner H Nakamura T Sasada J Yodoi A Holmgren G Spyrou 2001 Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum(II) and its major metabolite, the glutathione-platinum complex Free Radic Biol Med 31 10 1170 1178 10.1016/S0891-5849(01)00698-0 1:CAS:528:DC%2BD3MXot1Olsb8%3D 11705695 doi:10.1016/S0891-5849(01)00698-0 (Pubitemid 33052492)
44. YT Su HL Chang SK Shyue SL Hsu 2005 Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway Biochem Pharmacol 70 2 229 241 10.1016/j.bcp.2005.04.026 1:CAS:528:DC%2BD2MXlt1Skt7s%3D 15941563 doi:10.1016/j.bcp.2005.04.026 (Pubitemid 40814405)
45. DR Green JC Reed 1998 Mitochondria and apoptosis Science 281 5381 1309 1312 10.1126/science.281.5381.1309 1:CAS:528:DyaK1cXlvVegsLo%3D 9721092 doi:10.1126/science.281.5381.1309
46. G Garcon F Zerimech M Hannothiaux P Gosset A Martin T Marez P Shirali 2001 Antioxidant defense disruption by polycyclic aromatic hydrocarbons-coated onto Fe2O3 particles in human lung cells (A549) Toxicology 166 3 129 137 10.1016/S0300-483X(01)00461-9 1:CAS:528:DC%2BD3MXmsFait7g%3D 11543909 doi:10.1016/S0300-483X(01)00461-9 (Pubitemid 32822794)
47. J Haendeler AM Zeiher S Dimmeler 1996 Vitamin C and E prevent lipopolysaccharide- induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax Eur J Pharmacol 317 2-3 407 411 10.1016/S0014-2999(96)00759-5 1:CAS:528:DyaK28XnsFSntb0%3D 8997628 doi:10.1016/S0014-2999(96)00759-5 (Pubitemid 27014049)
48. G Vera A Chiarlone MI Martin R Abalo 2006 Altered feeding behaviour induced by long-term cisplatin in rats Auton Neurosci 126-127 81 92 10.1016/j.autneu.2006.02.011 1:CAS:528:DC%2BD28XlsVentbc%3D 16567130 doi:10.1016/j.autneu.2006.02.011 (Pubitemid 43816923)